Skip to search formSkip to main contentSkip to account menu

candoxatril

Known as: 3-(1-((4-carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antihypertensive AgentsIndansPropionatesProtease Inhibitors

Narrower (1)

UK 79300

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.
Highly Cited
2010
Highly Cited
2010
Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity
The objective of this study was to determine the effect of AVE7688, a drug that inhibits both angiotensin converting enzyme (ACE… 
Highly Cited
2008
Highly Cited
2008
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedema
Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clinical trial in… 
Highly Cited
2005
Highly Cited
2005
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
Aims/hypothesisThe incretin hormone glucagon-like peptide 1 (GLP-1) has antihyperglycaemic effects, but its therapeutic… 
Highly Cited
2003
Highly Cited
2003
The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.
AIMS Candoxatril is a specific neutral endopeptidase (NEP) 24.11 inhibitor, and previous work has documented the effect of NEP… 
1999
1999
The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man.
Candoxatril (UK-79300) is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of (+/-)candoxatrilat (UK… 
1999
1999
Me-DuPHOS-Rh-Catalyzed Asymmetric Synthesis of the Pivotal Glutarate Intermediate for Candoxatril.
A greatly improved process has been developed for synthesis of the glutarate derivative 2, a key intermediate required for Pfizer… 
1998
1998
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
AIMS To assess the effect of candoxatril, a novel neutral endopeptidase inhibitor, on exercise capacity, clinical status and… 
1997
1997
Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril.
1. Candoxatrilat, an active neutral endopeptidase inhibitor, was released rapidly from the inactive prodrug candoxatril in vivo… 
Highly Cited
1992
Highly Cited
1992
Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension
Objective: Candoxatril (UK 79,300) is an orally available inhibitor of the neutral endopeptidase (E.C.3.4.24.11) which degrades… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)